UCB has acquired a biotech spin out from Duke University to support its ongoing commitment to develop pioneering new therapies.
Global biopharma, UCB, advances new innovations designed to ‘transform the lives of people living with severe diseases in immunology and neurology’. And the $30 million investment in Element Genomics will allow it to tap into the spin outs tech – built to ‘improve understanding of genome structure’.
“Element Genomics researchers have a stellar reputation and their scientific expertise in genomics and epigenomics will complement UCB’s, allowing us to deepen our understanding of disease mechanisms with the aim of developing targeted therapies. We look forward to working with the Element Genomics team and welcome them within UCB,” said Dhavalkumar Patel, UCB’s Chief Scientific Officer.
Element Genomics will remain at its offices in Durham, North Carolina, and will collaborate with UCB’s global research teams.